Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celldex Therapeutics
Biotech
Celldex drops phase 1 tumor bispecific to focus on inflammation
Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in inflammation.
James Waldron
Nov 7, 2024 7:25am
Celldex anti-cKIT antibody reduces hives in another phase 2 test
Jul 30, 2024 5:50am
Celldex laces up next to Big Pharmas with chronic hive drug
Nov 6, 2023 10:17am
After cancer flops, Celldex shows promise in treating hives
Jul 12, 2021 8:05am
Novel two-drug combo teaches immune system to attack cancer
Apr 8, 2019 11:00am
Celldex plans life after glembatumumab failure
May 11, 2018 9:42am
